Brief: Protara Therapeutics Announces Dosing Of First Patient In Phase 2 Starborn-1 Trial Of Tara-002 In Pediatric Patients
23/10/2023 13:11
Oct 23 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE
2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC PATIENTS WITH
LYMPHATIC MALFORMATIONS
Source text for Eikon: ID:nGNX9V3TCQ
Further company coverage: TARA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses